Greece

Carealia
Action

Intelligent healthcare design for dementia patients, using technology (e.g. wearable devices) to monitor and combine multiple life aspects, which allows clinicians with a holistic picture of behavioural patterns and symptoms. This will help to create personalized care for dementia patients, and has been shown through clinical trials to be useful in a number of different European countries.

Overview

Carealia (2016-present) builds upon the findings of Dem@Care (www.demcare.eu) from FP7, and uses now privately funded eHealth technology to monitor the condition of dementia patients and remotely support them. The Carelia team, composed of clinical psychologists, IT and market experts, also uses the extensive data collected by the ICT they implement in homes in order to deepen our understanding of dementia’s progression and possible treatments.

Because the company was founded out of a research programme, their methods are evidence-based and are already proven to be effective at a clinical level. This has allowed it to be transferred from Greece, the country in which it started, to pilots in Sweden, Ireland and France. They have further plans to expand with online cloud and multilingual services.  

Impact

Using this technology alleviates a substantial burden on informal carers and house nurses, as the routine monitoring is done by the technology instead and sent directly to the nurses. Nurses can therefore more effectively focus their efforts on where they are most needed, helping deliver more efficient care to those who need it most when they need it most.

This service is also a cost-effective way of providing monitoring and diagnosis for dementia patients. The service costs 100 EUR monthly/1200 EUR annually, whereas people can spend anywhere from 1000-5000 EUR annually for traditional care services. It provides a greater level of financial stability through its subscription service; if a patient’s condition deteriorates their fees will not go up as significantly as through traditional care.